What is the best strategy for slowly developing blastocysts?


Journal

Journal of gynecology obstetrics and human reproduction
ISSN: 2468-7847
Titre abrégé: J Gynecol Obstet Hum Reprod
Pays: France
ID NLM: 101701588

Informations de publication

Date de publication:
Sep 2022
Historique:
received: 16 03 2021
revised: 04 05 2022
accepted: 27 05 2022
pubmed: 1 6 2022
medline: 31 8 2022
entrez: 31 5 2022
Statut: ppublish

Résumé

Day 5 fresh blastocyst transfers results in higher clinical pregnancy and live birth rates than day 6 fresh blastocyst transfer. This study aimed to identify the strategy to adopt with slowly developing blastocysts. Should not fully expanded blastocyst on day 5 be transferred on day 5, or when expanded on day 6, or be frozen? 1093 single blastocyst transfer cycles performed between January 2016 and December 2018 were divided in 4 groups: day 5 fresh transfers of full or expanded blastocyst (≥B3), day 5 fresh transfers of slowly developing blastocysts (B1 or B2), day 6 fresh transfers of expanded blastocysts (≥B4), day 6 frozen-thawed single blastocyst transfer cycles. Clinical pregnancy rate and live birth rate were significantly higher with fresh expanded blastocyst transfer on day 5 than in any other group. No statistical difference could be found between the other 3 groups. Slowly developing day 5 blastocysts have poorer implantation potential than expanded day 5 blastocysts but can be fresh transferred on day 5 rather than being cultured until day 6 for transfer or freezing when no expanded blastocyst is available on day 5.

Identifiants

pubmed: 35640804
pii: S2468-7847(22)00097-6
doi: 10.1016/j.jogoh.2022.102414
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102414

Informations de copyright

Copyright © 2022 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no conflict of interest.

Auteurs

Sophie Loubersac (S)

CHU Nantes, Nantes Université, Service de Medecine et Biologie de la Reproduction et Gynecologie Medicale, Nantes, France; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation ans Translational Immunology, UMR 1064, F-44000 Nantes, France; Université de Nantes, Nantes, France.

Anaïs Inquel (A)

CHU Nantes, Nantes Université, Service de Medecine et Biologie de la Reproduction et Gynecologie Medicale, Nantes, France.

Tiphaine Lefebvre (T)

CHU Nantes, Nantes Université, Service de Medecine et Biologie de la Reproduction et Gynecologie Medicale, Nantes, France; Université de Nantes, Nantes, France.

Jenna Lammers (J)

CHU Nantes, Nantes Université, Service de Medecine et Biologie de la Reproduction et Gynecologie Medicale, Nantes, France; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation ans Translational Immunology, UMR 1064, F-44000 Nantes, France; Université de Nantes, Nantes, France.

Paul Barriere (P)

CHU Nantes, Nantes Université, Service de Medecine et Biologie de la Reproduction et Gynecologie Medicale, Nantes, France; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation ans Translational Immunology, UMR 1064, F-44000 Nantes, France; Université de Nantes, Nantes, France.

Thomas Freour (T)

CHU Nantes, Nantes Université, Service de Medecine et Biologie de la Reproduction et Gynecologie Medicale, Nantes, France; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation ans Translational Immunology, UMR 1064, F-44000 Nantes, France; Université de Nantes, Nantes, France.

Arnaud Reignier (A)

CHU Nantes, Nantes Université, Service de Medecine et Biologie de la Reproduction et Gynecologie Medicale, Nantes, France; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation ans Translational Immunology, UMR 1064, F-44000 Nantes, France; Université de Nantes, Nantes, France. Electronic address: arnaud.reignier@chu-nantes.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH